583 related articles for article (PubMed ID: 2532984)
1. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
2. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
de Greef WJ; Dullaart J; Zeilmaker GH
J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
[TBL] [Abstract][Full Text] [Related]
3. Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome.
Fiad TM; Cunningham SK; McKenna TJ
Eur J Endocrinol; 1996 Sep; 135(3):335-9. PubMed ID: 8890725
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
6. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.
Larrea F; Sandoval JL; Salinas E; Franco-Rodriguez VA; Méndez I; Ulloa-Aguirre A
Clin Endocrinol (Oxf); 1995 Nov; 43(5):591-600. PubMed ID: 8548944
[TBL] [Abstract][Full Text] [Related]
7. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
8. [Pathophysiology of gonadotropin secretion in patients with idiopathic precocious puberty and follow up studies during and after therapy with medroxyprogesterone acetate (author's transl)].
Aono T; Minagawa J; Terakawa N; Kurachi K; Matsumoto K
Nihon Naibunpi Gakkai Zasshi; 1975 Nov; 51(11):898-907. PubMed ID: 1241847
[TBL] [Abstract][Full Text] [Related]
9. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
10. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
Christman GM; Randolph JF; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
[TBL] [Abstract][Full Text] [Related]
11. Effects of medroxyprogesterone acetate in women with polycystic ovary syndrome.
Petsos P; Ratcliffe WA; Anderson DC
Clin Endocrinol (Oxf); 1986 Dec; 25(6):651-60. PubMed ID: 2958179
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
Guerin JF; Rollet J
Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
[TBL] [Abstract][Full Text] [Related]
14. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome.
Venturoli S; Porcu E; Fabbri R; Magrini O; Gammi L; Paradisi R; Forcacci M; Bolzani R; Flamigni C
Clin Endocrinol (Oxf); 1988 Jan; 28(1):93-107. PubMed ID: 3139335
[TBL] [Abstract][Full Text] [Related]
15. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
16. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease.
Rossmanith WG; Wirth U; Benz R; Wolf AS
Gynecol Endocrinol; 1989; 3(1):21-34. PubMed ID: 2658471
[TBL] [Abstract][Full Text] [Related]
17. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
Cheung AP; Lu JK; Chang RJ
Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
[TBL] [Abstract][Full Text] [Related]
18. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
[TBL] [Abstract][Full Text] [Related]
19. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
20. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
